Public assessment summary report for DOVPRELA (Pretomanid Tablets 200 mg)
Public assessment summary report for DOVPRELA (Pretomanid Tablets 200 mg)
Summary of product characteristics for Isoniazid 100mg and 300mg tablets
Summary of product characteristics for Isoniazid 100mg and 300mg tablets
Public assessment summary report for Isoniazid 100 and 300 mg tablets
Public assessment summary report for Isoniazid 100 and 300 mg tablets
PRIVACY POLICY
PRIVACY POLICY Last updated March 30, 2022 This privacy notice for Ethiopian Food and Drug Authority (doing business as EFDA) (“EFDA,” “we,” “us,” or “our”), describes how and why we might collect, store, use, and/or share (“process”) your information when you use our services (“Services”), such as when you: Visit our website at www.efda.gov.et, or…
Hemlibra_Emicizumab_ Summary of product characteristics v1
Hemlibra_Emicizumab_ Summary of product characteristics v1
Hemlibra_Emicizumab_ Public assessment summary reportv1
Hemlibra_Emicizumab_ Public assessment summary reportv1
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics
INIGAST 40 Public assessment summary report v1
INIGAST 40 Public assessment summary report v1
INIGAST 40 Summary of product characteristics v1
INIGAST 40 Summary of product characteristics v1